The latest price target for Actinium Pharmaceuticals (AMEX:ATNM) was reported by Stephens & Co. on March 31, 2026. The analyst firm set a price target for $5.00 expecting ATNM to fall to within 12 months (a possible NaN% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Actinium Pharmaceuticals (AMEX:ATNM) was provided by Stephens & Co., and Actinium Pharmaceuticals reiterated their overweight rating.

There is no last upgrade for Actinium Pharmaceuticals

There is no last downgrade for Actinium Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Actinium Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Actinium Pharmaceuticals was filed on March 31, 2026 so you should expect the next rating to be made available sometime around March 31, 2027.

While ratings are subjective and will change, the latest Actinium Pharmaceuticals (ATNM) rating was a reiterated with a price target of $5.00 to $5.00. The current price Actinium Pharmaceuticals (ATNM) is trading at is $undefined, which is out of the analyst’s predicted range.